Tripartite motif 25 ameliorates doxorubicin-induced cardiotoxicity by degrading p85α

Cell Death Dis. 2022 Jul 23;13(7):643. doi: 10.1038/s41419-022-05100-4.

Abstract

Doxorubicin (DOX)-based chemotherapy is widely used to treat malignant tumors; however, the cardiotoxicity induced by DOX restricts its clinical usage. A therapeutic dose of DOX can activate ubiquitin-proteasome system. However, whether and how ubiquitin-proteasome system brings out DOX-induced cardiotoxicity remains to be investigated. Here we conducted a proteomics analysis of a DOX-induced cardiotoxicity model to screen the potentially ubiquitination-related molecules. Dysregulated TRIM25 was found to contribute to the cardiotoxicity. In vivo and in vitro cardiotoxicity experiments revealed that TRIM25 ameliorated DOX-induced cardiotoxicity. Electron microscopy and endoplasmic reticulum stress markers revealed that TRIM25 mitigated endoplasmic reticulum stress and apoptosis in DOX-induced cardiomyocytes. Mechanistically, the Co-immunoprecipitation assays and CHX pulse-chase experiment determined that TRIM25 affected p85α stability and promoted its ubiquitination and degradation. This leads to increase of nuclear translocation of XBP-1s, which mitigates endoplasmic reticulum stress. These findings reveal that TRIM25 may have a therapeutic role for DOX-induced cardiotoxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis
  • Cardiotoxicity* / drug therapy
  • Cardiotoxicity* / etiology
  • Cardiotoxicity* / metabolism
  • Doxorubicin / pharmacology
  • Humans
  • Myocytes, Cardiac / metabolism
  • Oxidative Stress
  • Proteasome Endopeptidase Complex* / metabolism
  • Ubiquitins / metabolism

Substances

  • Ubiquitins
  • Doxorubicin
  • Proteasome Endopeptidase Complex